Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Covid-19 divides the biggest medtechs
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Covid-19 takes a toll on medtech’s first quarter
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Joint makers report pandemic pain
Sales of implants are set to fall sharply as non-urgent procedures are deferred.
A thoroughly average year for medtech mergers
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
Meril Life Sciences comes late to aortic valves
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
